Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

This study has been completed.
Sponsor:
Collaborators:
Takeda Pharmaceuticals North America, Inc.
Information provided by:
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00227110
First received: September 23, 2005
Last updated: October 12, 2009
Last verified: October 2009